Crinetics Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Crinetics Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Commercial-stage endocrine specialist with first-to-market acromegaly therapy and promising late-stage pipeline backed by strong balance sheet. PALSONIFY is the first FDA-approved oral treatment for acromegaly, representing significant commercial validation. In December 2025, atumelnant entered Phase 3 clinical trials for congenital adrenal hyperplasia, demonstrating strong pipeline momentum. Recent $350M financing.
What is Crinetics Pharmaceuticals, Inc.'s industry? Crinetics Pharmaceuticals, Inc. (crinetics.com) operates in Biopharmaceutical - Specialty Endocrinology. AskCyborg classifies Crinetics Pharmaceuticals, Inc. under Biopharmaceutical - Specialty Endocrinology in its company registry.
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment...
Cyborg Score thesis
Commercial-stage endocrine specialist with first-to-market acromegaly therapy and promising late-stage pipeline backed by strong...
Read the full analyst-debate transcript →Get the Latest Crinetics Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCrinetics Pharmaceuticals, Inc. Overview
Pro stress-test →Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Strategic Profile
Pro stress-test →Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. The company raised approximately $350 million in gross proceeds from a January 2026 public offering to fund PALSONIFY launch and an extensive pipeline of 10+ programs in clinical development.
Competitive Landscape
Pro stress-test →Crinetics is a clinical-stage to early-commercial pharmaceutical company in the rare endocrine diseases and endocrine-related tumors space, with paltusotine in Phase 3 development. Primary competitors are established endocrine specialists and diversified pharma companies with competing acromegaly and CAH treatments, though PALSONIFY's first-to-market oral status represents a significant competitive advantage.
Industry Context
Crinetics Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Endocrinology.
Key facts
Founded: 2008 · Headquarters: San Diego, US · Revenue: $1.0M